ctDNA-guided switch to camizestrant delays progression in ESR1-mutated breast cancer

A novel approach using circulating tumour DNA (ctDNA) to guide early treatment changes in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer has demonstrated significant clinical benefit, according to the phase 3 SERENA-6 trial. Prof. Nick Turner (Royal Marsden Hospital, UK) presented the results of the phase 3 SERENA-6 (NCT04964934), in which participants with oestrogen receptor 1 (ESR1) mutations detected via ctDNA prior to any clinical or radiographic signs of progression switched from aromatase inhibitor therapy to the next-generation oral selective oestrogen receptor degrader camizestrant, while continuing treatment with a CDK4/6 inhibitor [1]. The findings were simultaneously published in the New England Journal of Medicine [2]. Out of the >3,250 participants monitored with ctDNA, 315 were randomised on...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025